Conditional Approval and Value-Based Pricing for New Health Technologies

References

• Adida E (2021) Outcome-based pricing for new pharmaceuticals via rebates. Management Sci. 67(2):892–913.Link, Google Scholar
• Ahuja VA, Alvarez C, Birge JR, Syverson C (2021) Enhancing regulatory decision making for postmarket drug safety. Management Sci. 67(12):7493–7510.Link, Google Scholar
• Alban A, Chick SE, Foster M (2023) Value-based clinical trials: Selecting recruitment rates and trial lengths in different regulatory contexts. Management Sci. 69(6):3516–3535.Link, Google Scholar
• Antoñanzas F, Juárez-Castelló C, Rodríguez-Ibeas R (2011) Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach. Health Econom. Policy Law 6(3):391–403.Crossref, Google Scholar
• Barnsley P, Cubi-Molla P, Fischer A, Towse A (2016) Uncertainty and risk in HTA decision making. Accessed September 2, 2022, https://www.ohe.org/publications/uncertainty-and-risk-hta-decision-making.Google Scholar
• Barton GR, Briggs AH, Fenwick EA (2008) Optimal cost-effectiveness decisions: The role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health 11(5):886–897.Crossref, Google Scholar
• Berdud M, Ferraro J, Towse A (2023) A theory on ICER pricing and optimal levels of cost-effectiveness thresholds: A bargaining approach. Frontiers Health Services 3:1055471.Crossref, Google Scholar
• Boggild M, Palace J, Barton P, Ben-Shlomo Y, Bregenzer T, Dobson C, Gray R (2009) Multiple sclerosis risk sharing scheme: Two year results of clinical cohort study with historical comparator. BMJ 339:b4677.Crossref, Google Scholar
• Bravo F, Corcoran TC, Long EF (2021) Flexible drug approval policies. Manufacturing Service Oper. Management 24(1):542–560.Link, Google Scholar
• Brouwer W, van Baal P, van Exel J, Versteegh M (2021) When is it too expensive? Cost-effectiveness thresholds and healthcare decision-making. Eur. J. Health Econom. 20:699–709.Google Scholar
• Chick SE, Gans N, Yapar O (2022) Bayesian sequential learning for clinical trials of multiple correlated medical interventions. Management Sci. 68(7):4919–4938.Link, Google Scholar
• Claxton K (1999) The irrelevance of inference: A decision-making approach to the stochastic evaluation of healthcare technologies. J. Health Econom. 18(3):341–364.Crossref, Google Scholar
• Claxton K (2007) OFT, VBP: QED? Health Econom. 16(6):545–558.Crossref, Google Scholar
• Claxton K, Briggs A, Buxton MJ, Culyer AJ, McCabe C, Walker S, Sculpher MJ (2008) Value based pricing for NHS drugs: An opportunity not to be missed? BMJ 336(7638):251–254.Crossref, Google Scholar
• Claxton K, Palmer S, Longworth L, Bojke L, Griffin S, Soares M, Spackman E, Rothery C (2016) A comprehensive algorithm for approval of health technologies with, without, or only in research: The key principles for informing coverage decisions. Value Health 19(6):885–891.Crossref, Google Scholar
• Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, Brazier J, O’Hagan T (2005) Probabilistic sensitivity analysis for NICE technology assessment: Not an optional extra. Health Econom. 14(4):339–347.Crossref, Google Scholar
• Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, Devlin N, Smith PC, Sculpher M (2015) Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol. Assessment 19(14):1–530.Crossref, Google Scholar
• ClinicalTrials.gov (2010) History of changes for study: NCT00720941. Submitted July 2010. Accessed May 6, 2019, https://clinicaltrials.gov/ct2/history/NCT00720941?V_78=View#StudyPageTop.Google Scholar
• Centers for Medicare and Medicaid Services (2014) Guidance for the public, industry, and CMS staff: Coverage with evidence development. Accessed July 15, 2022, https://www.cms.gov/Medicare/Coverage/Coverage-with-Evidence-Development.Google Scholar
• Critchley GJ, Zaric GS (2019) The impact of pharmaceutical marketing on market access, treatment coverage. and social welfare. Health Econom. 28:1035–1051.Crossref, Google Scholar
• Danzon PM, Drummond MF, Towse A, Pauly MV (2018) Objectives, budgets, thresholds, and opportunity costs—A health economics approach: ISPOR special task force report [4]. Value Health 21(2):140–145.Crossref, Google Scholar
• Eckermann S, Willan AR (2007) Expected value of information and decision making in HTA. Health Econom. 16(2):195–209.Crossref, Google Scholar
• European Medicines Agency (2022) Authorisation of medicines. Accessed June 14, 2022, https://www.ema.europa.eu/en/about-us/what-we-do/authorisation-medicines.Google Scholar
• Emanuel EJ, Zhang C, Glickman A, Gudbranson E, DiMagno SSP, Urwin JW (2020) Drug reimbursement regulation in 6 peer countries. JAMA Internal Medicine 180(11):1510–1517.Crossref, Google Scholar
• European Commission (2018) Opinion on innovative payment models for high-cost innovative medicines. Accessed May 15, 2022, https://data.europa.eu/doi/10.2875/049700.Google Scholar
• Gamba S, Pertile P, Vogler S (2020) The impact of managed entry agreements on pharmaceutical prices. Health Econom. 29:47–62.Crossref, Google Scholar
• Gandjour A (2009) Pharmaceutical risk-sharing agreements. PharmacoEconomics 27(5):431.Crossref, Google Scholar
• Garrison LP Jr, Towse A, Briggs A, de Pouvourville G, Grueger J, Mohr PE, Severens JLH, et al. (2013) Performance-based risk-sharing arrangements—Good practices for design, implementation, and evaluation: Report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health 16(5):703–719.Crossref, Google Scholar
• Gavious A, Greenberg D, Hammerman A, Segev E (2014) Impact of a financial risk-sharing scheme on budget-impact estimations: A game-theoretic approach. Eur. J. Health Econom. 15(5):553–561.Crossref, Google Scholar
• Gladwell D, Bulement A, Cowell W, Patterson K, Strong M (2020) “Stick or twist?” Negotiating price and data in an era of conditional approval. Value Health 23(2):191–199.Crossref, Google Scholar
• Griffiths C, Hay N, Sutcliffe F, Stevens A (2011) NICE guidance on pazopanib for first-line treatment of advanced renal-cell carcinoma. Lancet Oncol. 12(3):221–222.Crossref, Google Scholar
• Grimm SE, Strong M, Brennan A, Wailoo AJ (2017) The HTA risk analysis chart: Visualising the need for and potential value of managed entry agreements in health technology assessment. PharmacoEconomics 35(12):1287–1296.Crossref, Google Scholar
• Hart O, Moore J (1988) Incomplete contracts and renegotiation. Econometrica 56(4):755–785.Crossref, Google Scholar
• Hill A, Gotham D, Fortunak J, Meldrum J, Erbacher I, Martin M, Shoman H, et al. (2016) Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment. BMJ Open 6(1):e009586.Crossref, Google Scholar
• Hlávka JP, Yu JC, Goldman DP, Lakdawalla DN (2021) The economics of alternative payment models for pharmaceuticals. Eur. J. Health Econom. 22(4):559–569.Crossref, Google Scholar
• Levaggi R (2014) Pricing schemes for new drugs: A welfare analysis. Soc. Sci. Med. 102:69–73.Crossref, Google Scholar
• Levaggi R, Pertile P (2020) Value-based pricing alternatives for personalised drugs: Implications of asymmetric information and competition. Appl. Health Econom. Health Policy 18(3):357–362.Crossref, Google Scholar
• Lippman SA, McCardle KF (2012) Embedded Nash bargaining: Risk aversion and impatience. Decision Anal. 9(1):31–40.Link, Google Scholar
• Mahjoub R, Ødegaard F, Zaric GS (2017) Evaluation of a pharmaceutical risk-sharing agreement when patients are screened for the probability of success. Health Econom. 27(1):e15–e25.Crossref, Google Scholar
• Mantopoulos T, Dias S, Ades A, Welton N (2015) External validity of RCT evidence in cost-effectiveness analyses. A review of recent technology appraisals for NICE and proposed methods of adjustment. Trials 16S2(P25):118–125.Google Scholar
• Medicines and Healthcare Products Regulatory Agency (2023) More information about the MHRA. Accessed August 28, 2024, https://www.gov.uk/government/publications/more-information-about-the-mhra.Google Scholar
• Moore TJ, Zhang H, Anderson G, Alexander GC (2018) Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016. JAMA Intern. Med. 178(11):1451–1457.Crossref, Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, et al. (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27(22):3584–3590.Crossref, Google Scholar
• NHS England (2016) Appraisal and funding of cancer drugs from July 2016 (including the new Cancer Drugs Fund). Accessed August 8, 2024, https://www.england.nhs.uk/publication/cdf-sop-16/.Google Scholar
• NHS England (2022) Innovative Medicines Fund. Accessed September 20, 2023, https://www.england.nhs.uk/medicines-2/innovative-medicines-fund/.Google Scholar
• National Institute for Health and Care Excellence (2009) Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma. Accessed August 28, 2024, https://www.nice.org.uk/guidance/ta169.Google Scholar
• National Institute for Health and Care Excellence (2011) Pazopanib for the first-line treatment of advanced renal cell carcinoma. Updated 2013. Accessed June 14, 2022, https://www.nice.org.uk/guidance/ta215.Google Scholar
• National Institute for Health and Care Excellence (2014) Developing NICE guidelines: The manual. Updated 2024. Accessed August 8, 2024, https://www.nice.org.uk/process/pmg20/chapter/introduction.Google Scholar
• National Institute for Health and Care Excellence (2021) Cancer Drugs Fund. Accessed September 20, 2023, https://www.nice.org.uk/about/what-we-do/our-programmes/managed-access.Google Scholar
• Organisation for Economic Co-operation and Development (2019) Health at a glance 2019: OECD indicators. OECD Publishing, Paris. Accessed September 14, 2021, https://doi.org/10.1787/4dd50c09-en.Google Scholar
• O’Hagan A, Stevens JW (2002) The probability of cost-effectiveness. BMC Med. Res. Methodol. 2(5):5.Crossref, Google Scholar
• O’Hagan A, Buck CE, Daneshkhah A, Eiser JR, Garthwaite PH, Jenkinson DJ, Oakley JE, Rakow T (2006) Uncertain Judgments: Eliciting Experts’ Probabilities (John Wiley & Sons, Hoboken, NJ).Crossref, Google Scholar
• Olsder W, Martagan T, Tang CS (2022) Improving access to rare disease treatments: Optimal subsidies, pricing, and payment. Management Sci. 69(9):5256–5274.Link, Google Scholar
• Panteli D, Eckhardt H, Nolting A, Busse R, Kulig M (2015) From market access to patient access: Overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries. Health Rese. Policy Systems 13:39.Crossref, Google Scholar
• Piatkiewicz TJ, Traulsen JM, Holm-Larsen T (2018) Risk-sharing agreements in the EU: A systematic review of major trends. PharmacoEconom. Open 2(2):109–123.Crossref, Google Scholar
• Sertkaya A, Birkenbach A, Berlind A, Eyraud J (2014) Examination of clinical trial costs and barriers for drug development. Report, U.S. Department of Health and Human Services, Washington, DC.Google Scholar
• UK Department of Health (2002) Cost effective provision of disease modifying therapies for people with multiple sclerosis. Health Service Circular 2002/004, Stationery Office, London.Google Scholar
• UK Department of Health and Social Care, Association of the British Pharmaceutical Industry (2018) The 2019 voluntary scheme for branded medicines pricing and access. Accessed April 10, 2022, https://www.gov.uk/government/publications/voluntary-scheme-for-branded-medicines-pricing-and-access.Google Scholar
• van de Wetering E, van Exel J, Brouwer WB (2017) The challenge of conditional reimbursement: Stopping reimbursement can be more difficult than not starting in the first place! Value Health 20:118–125.Crossref, Google Scholar
• Walker S, Sculpher M, Claxton K, Palmer S (2012) Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. Value Health 15(3):570–579.Crossref, Google Scholar
• Whittal A, Jommi C, De Pouvourville G, Taylor D, Annemans L, Schoonaert L, Vermeersch S, et al. (2022) Facilitating more efficient negotiations for innovative therapies: A value-based negotiation framework. Internat. J. Tech. Assessment Healthcare 38(1):e23.Google Scholar
• Willis M, Persson U, Zoellner Y, Gradl B (2010) Reducing uncertainty in value-based pricing using evidence development agreements. Appl. Health Econom. Health Policy 8(6):377–386.Crossref, Google Scholar
• Wouterse B, van Baal P, Versteegh M, Brouwer W (2023) The value of health in a cost-effectiveness analysis: Theory vs. practice. PharmacoEconomics 41(6):607–617. Google Scholar
• Xu L, Li H, Zhao H (2022) Outcome-based reimbursement: The solution to high drug spending? Manufacturing Serv. Oper. Management 24(4):2029–2047.Link, Google Scholar
• Zampirolli Dias C, Godman B, Peres Gargano L, Santos Azevedo P, Morgado Garcia M, Souza Cazarim M, Neiva Pantuzza LL, et al. (2020) Integrative review of managed entry agreements: Chances and limitations. PharmacoEconomics 38(11):1165–1185.Crossref, Google Scholar
• Zaric GS (2021) How risky is that risk sharing agreement? Mean-variance tradeoffs and unintended consequences of six common risk sharing agreements. MDM Policy Practice 6(1):2381468321990404.Crossref, Google Scholar
• Zaric GS, Xie B (2009) The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits. Value Health 12(5):838–845.Crossref, Google Scholar
• Zhang H, Zaric GS (2015) Using price–volume agreements to manage pharmaceutical leakage and off-label promotion. Eur. J. Health Econom. 16(7):747–761.Crossref, Google Scholar
• Zhang H, Zaric GS, Huang T (2011) Optimal design of a pharmaceutical price–volume agreement under asymmetric information about expected market size. Production Oper. Management 20(3):334–346.Crossref, Google Scholar
• Zorc S, Chick SE, Hasija S (2024) Outcomes-based reimbursement policies for chronic care pathways. Preprint, submitted July 24, https://dx.doi.org/10.2139/ssrn.2973048.Google Scholar